Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Gastric & gastro-oesophageal junction cancer, drawn from the whole corpus: 173 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
3 medicines on record are linked to one of the types below rather than to Gastric & gastro-oesophageal junction cancer itself. Grouped by the type that holds them; each list opens that type's own page.
Peritoneal metastasis.
Background: Peritoneal metastasis. Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Heterogeneous CLDN18.2/HER2 expression.
Screening only in Japan/Korea.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Peritoneal metastasis is the dominant relapse pattern and is poorly imaged, poorly penetrated by drugs, and excluded from most trials.
Background: Peritoneal metastasis. Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Diffuse-type and genomically stable tumours lack targets and respond poorly to chemotherapy and immunotherapy.
Nothing recorded yet.
Nothing recorded yet.
Background: RAS / RAF / MEK / ERK (MAPK). Also on OnCo: Targets · KRAS roadmap.
Biomarker overlap (CLDN18.2 with PD-L1) has no randomised guidance on combination versus sequence.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
HER2 and CLDN18.2 expression are heterogeneous and can be lost at progression; re-biopsy or ctDNA before second-line targeting is not standard.
No Western screening strategy; most patients present with advanced disease.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
FGFR2b benefit is uncertain after FORTITUDE-101; the control arm lacked immunotherapy.
Perioperative immunotherapy benefit by PD-L1 or MSI status, and whether chemotherapy can be omitted in MSI-high disease, are unresolved.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 75 changes by month →When this page itself was last checked or edited.
FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma
First-line HER2-positive gastric, gastro-oesophageal junction or oesophageal adenocarcinoma with tislelizumab and fluoropyrimidine-platinum chemotherapy
Co-primary endpoints including OS met (July 2026); numbers pending.
PFS 12.
A milestone in how this cancer is treated.